CircRNA14781, a member of the burgeoning family of circular RNAs, exhibits intriguing regulatory capabilities that can influence gene expression. In this study, the authors illustrate how CircRNA14781 operates through the modulation of microRNA networks, specifically targeting miR-330-5p. This microRNA has been previously implicated in various cellular processes, including proliferation, apoptosis, and drug resistance. The relationship between CircRNA14781 and miR-330-5p is critical, as it reveals a novel regulatory axis that potentially alters the cellular response to chemotherapy.

One of the most striking findings of this research is the impact of CircRNA14781 on the expression of the nerve growth factor receptor, commonly referred to as NGFR. The study demonstrates that elevated levels of CircRNA14781 correlate with increased expression of NGFR, suggesting that this circular RNA acts as a sponge for miR-330-5p. This sponging mechanism effectively reduces the availability of miR-330-5p to target its mRNA sites, leading to enhanced NGFR expression. This axis of regulation clearly illustrates how non-coding RNAs can influence gene expression and contribute to therapeutic resistance.

The authors conducted comprehensive experiments to validate their hypotheses. Using ovarian cancer cell lines subjected to olaparib treatment, they observed a notable increase in CircRNA14781 expression in resistant cells compared to sensitive counterparts. Conversely, knocking down CircRNA14781 significantly restored sensitivity to olaparib, underscoring its functional role in mediating drug resistance. These findings highlight the potential of CircRNA14781 as a biomarker for therapy response, as well as a therapeutic target in resistant ovarian cancer.

The pathway involving miR-330-5p and NGFR is particularly important, as NGFR is known to play a pivotal role in cancer cell survival and proliferation. By boosting NGFR levels, CircRNA14781 may confer a survival advantage to ovarian cancer cells, allowing them to withstand the cytotoxic effects of olaparib. The study meticulously details the biochemical pathways involved, providing a robust framework for understanding how this circular RNA can disturb the balance between cell survival and death in the context of cancer treatment.

Moreover, the research offers compelling evidence for the potential therapeutic applications of targeting CircRNA14781. By designing agents that can inhibit the action of CircRNA14781, it might be possible to re-sensitize ovarian cancer cells to olaparib and other agents used in clinical oncology. These findings open avenues for innovative treatment strategies that could significantly improve patient outcomes and offer hope where traditional approaches fail.

One of the crucial aspects of this research lies in its contribution to the broader understanding of circular RNAs in cancer biology. The study builds upon existing literature that has highlighted the multifaceted roles of these non-coding RNAs in various malignancies. As the understanding of circRNAs deepens, it is becoming increasingly clear that these molecules are not merely byproducts of gene expression but potent regulators that can influence cancer progression and treatment responses.

In the context of ovarian cancer, where treatment resistance is rampant and complicates clinical management, the identification of CircRNA14781 as a contributor to olaparib resistance is particularly timely. The research not only elucidates a novel mechanism of resistance but also emphasizes the need for continued exploration into the role of non-coding RNAs in cancer. As molecular biology advances, the identification of new therapeutic targets is critical, and studies like this underscore the potential of RNA-based therapies.

This research aligns with ongoing efforts in cancer therapeutics to personalize treatment strategies. By understanding the molecular intricacies of drug resistance mechanisms, clinicians can tailor interventions that circumvent these barriers, potentially leading to more effective outcomes for patients. The implications of CircRNA14781 extend beyond the laboratory, promising to impact clinical approaches to treating ovarian cancer and perhaps other malignancies influenced by similar mechanisms of resistance.

As this field of study evolves, continuous efforts will be required to translate these findings from bench to bedside. The challenges of implementing new therapies based on RNA modulation must be addressed thoughtfully, considering factors like delivery mechanisms, safety, and efficacy. Nonetheless, the preliminary findings surrounding CircRNA14781 offer a hopeful glimpse into the future of cancer therapy, where understanding the molecular underpinnings of resistance can lead to revolutionary changes in treatment paradigms.

In conclusion, the research led by Chen et al. underscores the significance of understanding circular RNAs in the context of ovarian cancer and drug resistance. The study’s findings not only highlight a previously unrecognized player in olaparib resistance but also set the stage for future investigations that could yield transformative therapies. As the scientific community continues to unravel the complexities of cancer biology, the potential for circular RNAs like CircRNA14781 to contribute to meaningful advancements in treatment remains a promising area of exploration.

Advancements in cancer research, such as those presented here, are vital as we strive for precision oncology—a future where therapies are tailored to the individual molecular profile of a patient’s tumor. Such personalized medicine holds the key to improving survival rates and quality of life for patients battling cancer, particularly in aggressive forms like ovarian cancer. As researchers build upon the findings of CircRNA14781 and its role in drug resistance, the hope is for a future in which no patient has to face the devastating impact of treatment-resistant cancer.

In summary, this study not only sheds light on the mechanisms of drug resistance in ovarian cancer but also signifies a shift in how we approach cancer treatment. By integrating knowledge from molecular biology and therapeutic discovery, we can foresee a landscape where treatment is not just about killing cancer cells but also about understanding the intricate dance of regulatory networks that govern their behavior. The journey toward effective cancer therapies is long and arduous, but with every discovery, we move closer to conquering this formidable disease.

Subject of Research: CircRNA14781 and its role in olaparib resistance in ovarian cancer cells.

Article Title: CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway.

Article References:

Chen, B., Zong, S., Tang, J. et al. CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway. J Ovarian Res (2026). https://doi.org/10.1186/s13048-025-01957-z

Image Credits: AI Generated

DOI:

Keywords: CircRNA, olaparib resistance, ovarian cancer, miR-330-5p, NGFR, non-coding RNA, cancer biology, drug resistance, therapeutic target.

At the University of Illinois Chicago, a multidisciplinary team consisting of surgeons, anesthesiologists, and engineers is making strides toward improving treatment outcomes for pancreatic cancer patients. Their groundbreaking research focuses on the impact of lidocaine, a widely used local anesthetic, on cancer cells shed into the bloodstream during surgical tumor removal. A recently published study in the journal Lab on a Chip describes novel advances in isolating these circulating tumor cells (CTCs) using innovative microfluidic technologies. This approach offers promising potential in mitigating metastatic spread during the vulnerable perioperative period.

Dr. Gina Votta-Velis, professor of anesthesiology at UIC College of Medicine and a principal investigator on the project, emphasizes the transformative potential of this research. Lidocaine, a mainstay in anesthesia for over six decades primarily for pain relief, may possess unrecognized anti-metastatic properties. Preliminary findings suggest that administering lidocaine intraoperatively could hinder the ability of CTCs to invade new tissues, thereby reducing the risk of cancer metastasis and ultimately enhancing patient prognoses.

In 2018, Dr. Votta-Velis secured funding from the American Society of Regional Anesthesia and Pain Medicine to explore this hypothesis. CTCs are cancer cells that detach from the primary tumor mass during surgery and enter systemic circulation. Their presence is strongly correlated with worse clinical outcomes and higher rates of tumor recurrence. Because these cells are exceedingly rare in blood compared to normal cells, capturing and studying them has remained a significant challenge in oncology.

Typically, patients must recover from surgery before commencing chemotherapy, creating a critical temporal window where CTCs can disseminate and seed secondary tumors. However, early in vitro experiments demonstrate that lidocaine may disrupt the ability of these cells to survive and exit the bloodstream. Instead, the anesthetic appears to facilitate their entrapment and subsequent clearance by immune cells. This innovative concept reframes lidocaine as not only an analgesic but also a potential agent to impede metastatic progression.

“Circulating tumor cells are essentially the seeds from which metastases grow,” explained Dr. Votta-Velis. “Identifying these cells and diminishing their virulence during critical treatment intervals offers an unprecedented approach to curtailing the metastatic cascade, which accounts for the majority of cancer-related deaths.” The implications for extending patient survival and quality of life could be profound.

The rarity and heterogeneity of CTCs present formidable obstacles to accurate isolation and analysis. To overcome the proverbial “needle in a haystack” problem, the UIC team collaborated with Dr. Ian Papautsky, a biomedical engineering professor specializing in microfluidics—the manipulation of tiny fluid volumes through microscale channels. The team developed a novel microfluidic device composed of glass and plastic, measuring just a few inches and containing narrow channels only slightly wider than a human hair. This platform exploits size differences to separate larger, softer cancer cells from smaller blood components, facilitating a gentle, label-free liquid biopsy.

In 2019, Dr. Papautsky’s group demonstrated the device’s remarkable efficacy, achieving 93 percent accuracy in identifying CTCs without damaging them. In the latest work, they compared their microfluidic technique to the widely used EasySep system, which relies on magnetic bead-based cell separation. Unlike magnetic methods that can be harsh and compromise cell integrity, the microfluidic device retrieves significantly more viable cancer cells at greater speed—processing patient blood samples in as little as 20 minutes with an eightfold increase in recovery rate.

“Early and accurate detection of CTCs is indispensable for silent cancers like pancreatic cancer, where routine imaging often fails to identify disease progression,” said Dr. Papautsky. “Our device enables minimally invasive diagnostics, opening the door for personalized treatment strategies that target metastatic mechanisms at their earliest stages.” This technological innovation complements clinical efforts to intercept cancer dissemination before it culminates in full-blown metastasis.

Dr. Pier Giulianotti, co-investigator and chief of general, minimally invasive, and robotic surgery at UIC College of Medicine, echoed the significance of these findings. A globally recognized expert in pancreatic cancer surgeries, he highlighted that most malignant tumors metastasize via the bloodstream. “Understanding how cancer cells enter circulation and developing methods to control this phenomenon is not just important—it is essential to transforming how we manage aggressive cancers,” he stated.

The research team also comprises UIC scholars Celine Macaraniag, Ifra Khan, Alexandra Barabanova, Valentina Valle, and Alain Borgeat, as well as Jian Zhou from Rush University Medical Center. Together, they are forging a multidisciplinary path at the intersection of engineering, anesthesiology, and oncology, paving the way for therapies that could revolutionize pancreatic cancer treatment.

This pioneering effort exemplifies how integration of advanced microfluidic technologies with clinical research can yield transformative insights and novel interventions. While pancreatic cancer remains a formidable adversary, such innovative approaches to intercepting circulating tumor cells offer a glimmer of hope for improving survival rates and patient outcomes in what is often considered a high-mortality disease.

Subject of Research: The interaction of lidocaine with circulating pancreatic cancer cells and advancements in microfluidic isolation techniques.

Article Title: Lidocaine’s Potential to Inhibit Metastasis: Microfluidic Innovations in Pancreatic Cancer Treatment

News Publication Date: Not specified in source content.

Web References:
– U.S. Cancer Statistics: https://seer.cancer.gov/statfacts/html/common.html
– Pancreatic Cancer Survival Rates: https://seer.cancer.gov/statfacts/html/pancreas.html
– American Society of Regional Anesthesia and Pain Medicine: https://asra.com/news-publications/asra-updates/blog-landing/legacy-b-blog-posts/2021/01/29/past-carl-koller-memorial-research-grant-recipients
– Lab on a Chip Article DOI: http://dx.doi.org/10.1039/D5LC00512D
– Microfluidic Cell Separation Accuracy: https://www.nature.com/articles/s41378-019-0045-6

References:
Lab on a Chip, DOI: 10.1039/D5LC00512D

Image Credits: Photo by Sana Sheybanikashani, University of Illinois Chicago

Keywords: Pancreatic cancer, Microfluidics, Circulating tumor cells, Lidocaine, Metastasis, Liquid biopsy, Biomedical engineering, Cancer diagnostics

Esophageal squamous cell carcinoma ranks among the deadliest of gastrointestinal cancers, with historically poor prognosis and limited long-term survival. Traditional treatment paradigms often involve surgery alone or in combination with chemotherapy and radiation, but recurrence rates remain worryingly high. The advent of immune checkpoint inhibitors, such as tislelizumab — a PD-1 inhibitor engineered to enhance antitumor immunity — integrated with chemotherapy offers a mechanistically innovative approach that seeks to amplify tumor eradication before surgical resection.

The TD-NICE trial enrolled 45 patients from September 2020 to March 2021, administering a regimen of tislelizumab alongside standard chemotherapy prior to surgery when feasible. What distinguishes this study is its rigorous four-year observation window, allowing an assessment not only of immediate tumor response but of durable survival outcomes. This timeline is critical in oncology, where disease relapse often emerges beyond the initial years of treatment, challenging long-term patient management.

The results reveal a striking trend: median overall survival (OS) and event-free survival (EFS) were not reached across the cohort, underscoring the robustness of response in this population. Specifically, survival probabilities at 12, 24, 36, and 48 months hovered at encouraging levels of 82.2%, 73.3%, 66.7%, and an estimated 66.2%, respectively. These figures suggest that the majority of patients experienced prolonged survival, a notable achievement given ESCC’s aggressive nature.

Crucially, the study delineated survival benefits in subgroups based on surgical intervention and surgical margins. Patients undergoing surgery demonstrated significantly superior outcomes compared to those who did not, with a p-value of 0.046 indicating statistical significance. Among surgical patients, those who achieved R0 resection — the complete removal of all visible tumor with negative margins — fared better than individuals with R1 or R2 resections, which indicate residual microscopic or macroscopic disease. The difference achieved statistical significance (p=0.041), emphasizing the importance of achieving clean margins in surgical oncology.

The study employed advanced statistical methodologies, including Kaplan-Meier survival curves and Cox proportional hazards modeling, to ensure the reliability and interpretability of these findings. By doing so, the research team could quantify the survival advantage and correlate it robustly with clinical parameters. This methodological rigor ensures that the observed benefits are not a product of chance, but reflect a true therapeutic advantage.

From a mechanistic standpoint, the synergy of chemotherapy with tislelizumab likely potentiates immune-mediated tumoricidal activity. Chemotherapy can increase the tumor’s antigenicity and foster immunogenic cell death, while PD-1 inhibition alleviates immune checkpoints that suppress T-cell activity. This combination primes the host immune system to mount a more effective and sustained attack against residual tumor cells, thus enhancing the efficacy of subsequent surgical excision.

Furthermore, improvement in event-free survival (EFS), which encompasses progression, relapse, or death, paralleled overall survival benefits. Both EFS in patients undergoing surgery versus those who did not and EFS comparing R0 resection to R1/R2 resection were statistically significant, underscoring the comprehensive impact of this multimodal treatment strategy on disease control. These endpoints collectively strengthen the case for integrating immunotherapy early in the treatment continuum.

The implications of these findings are multifaceted. Clinically, they support the incorporation of neoadjuvant chemoimmunotherapy protocols prior to esophagectomy as a standard of care for suitable patients. This approach not only enhances survival chances but might also optimize patient selection for surgery by downstaging tumors and improving resectability. Moreover, it underscores the necessity of meticulous surgical technique to achieve R0 resections, which remain pivotal in securing long-term remission.

Beyond clinical practice, this study fuels scientific enquiry into the interplay between immune modulation and cytotoxic treatments in solid tumors. As immunotherapy gains traction across various malignancies, understanding the nuances of timing, combination, and patient stratification becomes paramount. The TD-NICE four-year data contribute critical evidence supporting the durability of immune-enhanced treatments, challenging pre-existing conceptions that immunotherapy benefits might be transient.

The trial registration (ChiCTR2000037488) and transparent reporting ensure that these promising results can be scrutinized, validated, and potentially built upon in larger phase 3 studies. Such investigations will be essential to confirm efficacy across broader patient populations and to clarify optimal dosing regimens, potential toxicities, and cost-effectiveness parameters.

In tandem, the tolerability profile and safety data, while not detailed in this interim report, remain an essential consideration. Prior phase 2 findings had highlighted manageable adverse events associated with tislelizumab plus chemotherapy, but long-term safety especially following surgery will require continued surveillance to ensure no late-onset complications undermine these survival gains.

From the perspective of patient experience, the integration of immunotherapy offers hope in a disease typically characterized by dismal outcomes. Enhanced survival prospects translate not only to extended life but to improved quality of life, psychological resilience, and reduced burden of disease recurrence, factors integral to comprehensive oncology care.

Concurrently, the TD-NICE study embodies a paradigm shift towards personalized medicine in ESCC treatment, where tumor biology, immune microenvironment, and surgical precision converge. It sets a precedent for future innovation, encouraging the development of biomarkers predictive of treatment response and resistance mechanisms that may emerge post-therapy.

While these findings represent a milestone, challenges persist. The relatively small sample size, characteristic of phase 2 trials, underscores the need for larger randomized controlled trials to validate and refine these observations. Additionally, the heterogeneous nature of ESCC worldwide necessitates studies across diverse ethnic and geographic populations to ensure generalizability.

In summation, the four-year follow-up from the TD-NICE phase 2 trial affirms that neoadjuvant administration of tislelizumab combined with chemotherapy, followed by surgery, significantly improves survival in patients with resectable esophageal squamous cell carcinoma. This chemoimmunotherapy approach heralds a new era of therapeutic strategy, driving the oncology field closer to durable remissions and perhaps eventual cures in a disease long marked by poor prognosis.

As research unfolds, the synergy between immune modulation and surgical oncology invites optimism that the lethality of ESCC can be attenuated. Clinicians, researchers, and patients alike will watch with keen interest as these preliminary results catapult us towards more effective, targeted, and personalized regimens that can rewrite the narrative of esophageal cancer.

Subject of Research: Neoadjuvant treatment with tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Article Title: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Article References:
Mao, Y., Gao, Z., Sun, Y. et al. Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma. BMC Cancer 25, 1328 (2025). https://doi.org/10.1186/s12885-025-14686-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14686-9